The above research indicates the use of CGM systems not only as a tool for glycemic control and improvement in treatment outcomes in insulin-treated diabetes but also as a diagnostic tool for T1D staging or assessing the impact of novel drugs on improving glycemic control. The gene discussed is INS; the disease is type 1 diabetes mellitus.